KRC-108
KRC-108, an aminopyridine, is an orally active multiple kinase inhibitor with IC50s of 80 nM, 23 nM, 3 nM, 70 nM, 30 nM, 39 nM for c-Met, c-Met M1250T, c-Met Y1230D, Ron, Flt3 and TrkA, respectively. KRC-108 induces cell cycle arrest, apoptotic cell death, and autophagy. KRC-108 exhibits anti-tumor activity in vivo in HT29 colorectal cancer, NCI-H441 lung cancer xenograft models in athymic BALB/c nu/nu mice.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 1146944-35-5
- Formule: C20H20N6O
- Masse moléculaire:360.41
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
|
c-Met 80 nM (IC50) |
c-Met M1250T 23 nM (IC50) |
c-Met Y1230D 3 nM (IC50) |
Ron 70 nM (IC50) |
Flt3 30 nM (IC50) |
TrkA 39 nM (IC50) |
ALK 780 nM (IC50) |
VEGFR2 1660 nM (IC50) |
Chemical Information
-
CAS No. 1146944-35-5
-
Masse moléculaire 360.41
-
Formule C20H20N6O
-
SMILES
NC1=NC=C(C=C1C2=NC3=CC=CC=C3O2)C4=CN(N=C4)C5CCNCC5
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
[1]. Sun-Young Han, et al. Evaluation of a multi-kinase inhibitor KRC-108 as an anti-tumor agent in vitro and in vivo. Invest New Drugs. 2012 Apr;30(2):518-23. [Content Brief]
[2]. Hyo Jeong Lee, et al. Characterization of KRC-108 as a TrkA Kinase Inhibitor with Anti-Tumor Effects. Biomol Ther (Seoul). 2022 Jul 1;30(4):360-367. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz